Xilio Therapeutics, Inc.

US$8.62As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:XLOHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (48.23%)
Div yield —
ROE (55.03%)
Biotechnology
Beta (5Y) (0.11)
PE TTM —
TSR TTM (22.72%)
Mkt cap US$56.72M
ROIC (42.07%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
24.56%
(11.74%)
Hold 12|1|2|7|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.22
0.22
0.24
0.27
26.10%
21.87%
34.37%
33.60%
Revenue$M
5.881
5.888
6.192
6.087
0.82%
1.66%
9.81%
8.60%
Peers (US$56.72M)
Cap (US$)
PE
56.15M
—
Capital
TTM
5Y
10Y
Leveragex
4.811
(0.108)
(0.105)
EBIT/Intx
0.191
0.206
0.163
Own earn%
(158.23)
43.81
47.45
Sh yield%
32.74
33.91
33.71
Owners
Insiders/Inst%
11.40
45.56
Short interest%
1.16
SBC / revenue%
2.02
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
18–29
$1 testx
—
Incr. ROIC%
3